Hochberg M C, Dorsch C A, Feinglass E J, Stevens M B
Arthritis Rheum. 1981 Jan;24(1):54-9. doi: 10.1002/art.1780240109.
The course of 81 patients with systemic lupus erythematosus (SLE) who had sera tested for antibody to extractable nuclear antigen (ENA) was studied to determine the effect of the presence of antiENA antibody on survivorship. There were no differences in percent survival between the patients with and without antibody to ENA or those with and without antibody to the ribonucleoprotein (RNP) component of ENA. We conclude that there is no prognostic advantage to the presence of either antiENA or antiRNP antibody in patients with SLE.
对81例系统性红斑狼疮(SLE)患者进行了研究,这些患者的血清接受了可提取核抗原(ENA)抗体检测,以确定抗ENA抗体的存在对生存率的影响。有抗ENA抗体的患者与无抗ENA抗体的患者之间,以及有ENA核糖核蛋白(RNP)成分抗体的患者与无该抗体的患者之间,生存率百分比没有差异。我们得出结论,SLE患者中存在抗ENA或抗RNP抗体并无预后优势。